AzTrials
AzTrials

Alzheimer's DiseasePhase 2NCT03656042

To Evaluate the Efficacy and Safety/Tolerability Profiles of G-CSF in Subjects With Mild to Moderate Alzheimer's Disease

A Phase 2 study testing Filgrastim (75mcg/0.3ml) in people with Alzheimer's Disease, run by Chang Gung Memorial Hospital at 1 site in Taiwan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

With the enrichment of living environment and the progress of medicine, the scale of aging population has increased in many countries of the world. Alzheimer's disease (AD), the leading cause of dementia, counts for approximately 60% to 70% in dementia in aged population. Read more about this study

Who is it for?
Ages 50 to 85 years
Conditions the study is for
Alzheimer's Disease
What is being tested?
Filgrastim (75mcg/0.3ml)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
21 participants
Where
1 siteTaiwan
Study dates
Mar 2009to Aug 2014
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Subject with age of at lease 50 years old and no more than 85 years old
  • Subject diagnosed of Alzheimer's disease; based on the criteria of The Diagnostic and Statistical Manual of Mental Disorders (DSM)-Ⅳ for dementia and those of National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Dementia and Related Disorder Association (NINCDS - ADRDA) and within 12-months CT/MRI brain scan supporting evidences.
  • Subject with Mini-Mental Examination (MMSE) scores of 12 to 26 (inclusive).
  • Subject with Clinical Dementia Rating (CDR) score of 1 (mild) or 2 moderate).
  • Subject with Modified Hachinski Ischemic score of 4.
  • Subject with a Hamilton Psychiatric Rating Scale for Depression score of 12.
Show all 9Show fewer
  • Female subject with child-bearing potential agrees to take reliable contraceptive method during the participation of the study (Females with no child-bearing potential have to be surgically sterilized or at least 2 years after post-menopausal).
  • Subject and subject's legally acceptable representative have given written informed consent.
  • A reliable caregiver is sufficiently familiar with the subject (as determined by the investigator) and is willing to provide accurate data.

Who cannot join

  • Subject has underwent any of the following treatment modalities with the respective time frames:
  • Anti-epileptic agents: Within 12 weeks of the screening visit,
  • Narcotic: within 12 weeks of the screening visit,
  • Immunosuppressants: within 12 weeks of the screening visit,
  • Hypnotics: within 24 hours of the screening visit or the randomization visit,
  • Lithium: within 2 weeks of the randomization visit,
Show all 24Show fewer
  • Succinylcholine-type muscle relaxants: within 2 weeks of the randomization visit,
  • Drugs or treatments known to cause major organ system toxicity: within 42 weeks of the randomization visit,
  • Tricyclic and tetracyclic anti-depressants: within 4 weeks of the screening visit,
  • Antiparkinsonian: Within12 weeks of the screening visit (Not including dopaminergic agent or peripheral anticholinergic agent at stable dose for at least 4 weeks of randomization visit),
  • Any medications for cognition enhancement: Within13 weeks of the screening visit(except for donepezil that has been maintained with a stable regimen for at least 12 weeks).
  • Subject is lactating, pregnant or plans to become pregnant,
  • Subject is cared primarily by nursing home,
  • Subject's AST or ALT is greater than 2 times of the upper limit or normal range.
  • Subject with diabetic history and with HbA1c > 8.5 %.
  • Subject with clinically significant medical or neurological disorders, other than AD, that may affect cognition (e.g., abnormal thyroid function tests, Vitamin B12 or folate deficiency, post-traumatic conditions Huntington's disease, Parkinson's disease, syphilis, probable/possible vascular dementia according to NINDS-AIREN criteria, active/uncontrolled seizure).
  • Subject with major psychiatric disorders.
  • Subject with spleen related disorders.
  • Subject with sickle cell disease.
  • Subject with myelodysplastic syndrome.
  • Subject with current diagnosis of acute stroke or history of acute stroke within 1 year.
  • Subject with allergy history to E. coli-derived proteins or G-CSF or donepezil.
  • Subject with cancer history and has received related therapy(ies) with in 2 years of entering this study.
  • Subject has participated other investigational study within 4 weeks of entering this study.

Trial locations and contacts

1 site in 1 country.

Taiwan1 site

  • Chang Gung Memorial Hospital

    Taoyuan, Taiwan R.o.c, 333

Other trials in Taiwan

About this study

Official title: A Open-label, No-treatment-controlled, Parallel, Pilot Phase Ⅱ Study to Evaluate the Efficacy and Safety/Tolerability Profiles of G-CSF in Subjects With Mild to Moderate Alzheimer's Disease

With the enrichment of living environment and the progress of medicine, the scale of aging population has increased in many countries of the world. Alzheimer's disease (AD), the leading cause of dementia, counts for approximately 60% to 70% in dementia in aged population. AD is a well-known neurodegenerative disease and characterized by the formation of neurofibrillary tangles and deposition of amyloid in the brain. It also affects more than 12 million patients worldwide and puts a tremendous burden on family caregivers and causes high nursing home costs for society. So far, the mechanisms of AD have not been elucidated and currently no curable treatment exists. Thus, clinical trials concerning the treatment of AD are in urgent expectation.

Granulocyte-colony stimulating factor (G-CSF) is a growth factor that presents in human body in small quantity and is known to promote the blood cell proliferation and differentiation. Previous studies showed injection of G-CSF could help release hematopoietic stem cell (HSCs) from bone marrow to the peripheral blood, and then migrate to repair damaged areas, e.g. heart tissue and ischemia brain tissue. We have found that G-CSF triggering release of stem cells from bone marrow shows the potential as an effective reagent for treatment of AD by using two AD mouse models. The one was generated by injecting the brains of normal mice with amyloid and another was by using a strain of transgenic mice which naturally exhibit Alzheimer's disease-like neuronal apoptosis and memory loss. Subcutaneous administration of G-CSF into mice significantly rescued their cognitive/memory functions.

G-CSF has already been widely used in clinical practice, for example, neutropenia caused by chemotherapy in cancer and bone marrow transplantation. The new finding shows G-CSF can release HSCs from bone marrow and these cells not only can pass through the blood-brain barrier but can selectively migrate to the region of damaged brain to improve neurological recovery. Thus, we conduct this clinical trial to investigate the potential effect of G-CSF for the cognitive function of AD patients. If successful, G-CSF could open up a new window for AD treatment which is less invasive and more effective than the current therapies.

Read the detailed description

This is a randomized open-label Phase 2 trial with parallel design using no-treatment group as control. Subjects in the treatment arm will receive subcutaneous G-CSF with the dosage of 10 microgram/kg/day, for 5 continuous days in the first week. The second dosage will be given in the 12 week. If subjects has received Donepezil already, the Donepezil will be concomitantly used in a stable dose (the same dose as pre-entering this study) during the study.

Background data and general medical history will be registered on the screening visit (Visit 1, started four weeks or less before Visit 2). Subjects fulfil the inclusion criteria 1) age between 50 to 85 years old; 2) those who were diagnosed as AD and the supporting evidences from the brain computed tomography or Magnetic Resonance Imaging scan within 12-months; 3) Mini-Mental State Examination scores of 10 to 26, and, 4) Clinical Dementia Rating score of 1 or 2. Subjects with clinically significant medical or neurological disorders, other than AD, that may affect cognition will be excluded Additional inclusion criteria included Modified Hachinski Ischemic score of ≤ 4, Hamilton Psychiatric Rating Scale for Depression score of ≤ 12and a reliable caregiver who is sufficiently familiar with the subject and is willing to provide the accurate data.

Participants will receive standard physical examination in all visits. Serum tests include complete blood count (CBC),total bilirubin, creatinine, blood urea nitrogen (BUN), uric acid, aspartate transaminase (AST), alanine transaminase (ALT), total protein, albumin, Vitamin B12, folate, T4, thyroid-stimulating hormone (TSH), HbA1c, rapid plasmin reagin (RPR)/Treponema pallidum haemagglutination (TPHA) will be also obtained.

Being tested
Filgrastim (75mcg/0.3ml)
Keywords
Dementia, Alzheimer's disease, Granulocyte-colony stimulating factor
Medical subject headings
Alzheimer Disease, Dementia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Filgrastim (75mcg/0.3ml)Drug

    Also called NEUPOGEN®

    Subjects who meet all eligible requirements for entry into the study will be randomized into one of the two treatment groups in 1:1 ratio as shown below:

    1. 10 microgram/kg/day, by sc, for 5 continuous days for the first week, rest for 11 weeks; repeat dosing regimen every 12-weekly (12 weeks / cycle) for 2 cycles
    2. Non-treatment
Study groups in NCT03656042
Study groupRoleWhat they receive
G-CSFExperimentalSubjects in the treatment group will receive Filgrastim (75mcg/0.3ml, NEUPOGEN®), 10 mic/kg/day, by sc, for 5 continuous days for the first week, rest for 11 weeks. Filgrastim will be given 12-weekly ( 12 weeks/cycle ) for 2 cycles.
Receives: Drug: Filgrastim (75mcg/0.3ml)
No-treatmentNo interventionNo-treatment group is used to control evaluation bias and potential time effect.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Alzheimer's Disease Assessment Scale, Cognitive subscale - Chinese version (ADAS-Cog-C)

    The total score ranges from 0 to 75 and the higher the score, the greater the impairment. ADAS-Cog-C has 11 items and each has its score range:

    Word Recall Task: maximum score = 10 Naming Task: maximum score = 5 Commands: maximum score = 5 Constructional Praxis: maximum score = 5 Ideational Praxis: maximum score = 5 Orientation: maximum score = 8 Word Recognition: maximum score = 12 Remembering Test Instructions: maximum score = 5 Spoken Language Ability: maximum score = 5 Word-Finding Difficulty: maximum score = 5 Comprehension: maximum score = 5 We measure the change from baseline in ADAS-Cog at 24-week visit.

    Measured: 24 weeks

Secondary outcomes (9)

  1. Mini-mental State Examination (MMSE)

    The Mini-Mental State Examination (MMSE) is a 30-point questionnaire.

    The score ranges are as follows:

    Orientation to time 5 Orientation to place 5 Registration 3 Attention and calculation 5 Recall 3 Language 2 Repetition 1 Complex commands 5

    Measured: Baseline, 12 weeks, 24 weeks and 48 weeks

  2. Clinical Dementia Rating Scale (CDR)

    The Clinical Dementia Rating Scale is a 5-point scale used to characterize six domains of cognitive and functional performance to Alzheimer disease and related dementias: Memory, Orientation, Judgment \& Problem Solving, Community Affairs, Home \& Hobbies, and Personal Care.

    In each domain, the severity degree of each symptom correspond to different rating score from 0(none) to 3(severe). The total score ranges from 0 to 18

    Measured: Baseline, 12 weeks, 24 weeks and 48 weeks

  3. AD Cooperative Study - Clinical Global Impression of change (ADCS-CGIC )

    Interviewer scores the severity as follow:

    1. Not impaired / not present
    2. Borderline impairment
    3. Mild impairment
    4. Moderate impairment
    5. Marked impairment
    6. Severe impairment
    7. very severe

    Measured: Baseline, 12 weeks, 24 weeks and 48 weeks

  4. Lawton and Brody Scale for Instrumental Activities of Daily Living (IADL)

    The test measures eight realms of function through self report, which attempt to assess everyday functional competence in the elderly. Each item is rated either dichotomously (0 = less able, 1 = more able) or trichotomously (1 = unable, 2 = needs assistance, 3 = independent) and sum the eight responses. The summary score ranges from 0 (low function, dependent) to 8 (high function, independent) for women and 0 through 5 for men.

    Measured: Baseline, 12 weeks, 24 weeks and 48 weeks

  5. Neuropsychiatric Inventory (NPI)

    The NPI originally examined 12 sub-domains of behavioral functioning Each domain is scored for frequency, severity and associated caregiver distress.

    Frequency:Rarely,Sometimes,Often,Very often Severity:Mild,Moderate,Severe Caregiver Distress:0(not at all),1(minimally),2(mildly),3(moderately),4(severely),5(very severely or extremely). Total score will range from Less than 20(symptoms are mild),20-50(symptoms are moderate) to 50 or over(symptoms are severe)

    Measured: Baseline, 12 weeks, 24 weeks and 48 weeks

  6. Ten-point clock test (TPCT)

    One point is given for each of the following numbers that falls in its proper eighth of the circle relative to the number 12: 1.2, 4,5,7, 8, 10, and 11. One point is given each to a short hand pointing at the number eleven, and a long hand pointing at the number two. The total score ranges from 0 to 10.

    Measured: Baseline, 12 weeks, 24 weeks and 48 weeks

  7. CD34+ cell number for G-CSF treatment group

    G-CSF may promote mobilizing bone marrow CD34+ stem cells. We will compare the CD34+ cell number between treatment and control group at the baseline and follow up sequential change in the treatment group.

    Measured: Baseline, 12 weeks, 24 weeks and 48 weeks

  8. Trail making test (TMT)(Part A))

    The Trail Making Test is a neuropsychological test of visual attention and task switching. Results for Trail making test A (Part A) is reported as the number of seconds required to complete the task; therefore, higher scores reveal greater impairment. The average time is 29 seconds. If the subject uses more than 78 seconds, cognitive deficient is impressed.

    Measured: Baseline, 12 weeks, 24 weeks and 48 weeks

  9. Change from baseline in whole brain volume determined by MRI

    Change from baseline in whole brain volume determined by MRI. MRI examination will be performed within 7 days before the start at the start of first cycle (Visit 2) and week-24 visit (Visit 10), to compare the change of whole brain volume.

    Measured: Baseline, 24 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Sep 2018
  2. Study startMar 2009
  3. Primary completionJul 2014
  4. Study completionAug 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
21 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03656042
Sponsor's protocol ID
96-0272A-ASAD-061202
Status last verified
Feb 2017
First submitted
23 Aug 2018
Last updated
4 Sep 2018
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: Individual participant data sets including IPD that underlie results in a publication have not yet decided to be shared under the consideration of patient privacy.

Publications

  • Alzheimer's Association. 2016 Alzheimer's disease facts and figures. Alzheimers Dement. 2016 Apr;12(4):459-509. doi: 10.1016/j.jalz.2016.03.001.

    PubMed 27570871

  • Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM. Alzheimer's disease. Lancet. 2016 Jul 30;388(10043):505-17. doi: 10.1016/S0140-6736(15)01124-1. Epub 2016 Feb 24.

    PubMed 26921134

  • Braak H, Del Tredici K. The preclinical phase of the pathological process underlying sporadic Alzheimer's disease. Brain. 2015 Oct;138(Pt 10):2814-33. doi: 10.1093/brain/awv236. Epub 2015 Aug 17.

    PubMed 26283673

  • Chartier-Harlin MC, Crawford F, Houlden H, Warren A, Hughes D, Fidani L, Goate A, Rossor M, Roques P, Hardy J, et al. Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature. 1991 Oct 31;353(6347):844-6. doi: 10.1038/353844a0.

    PubMed 1944558

  • Tigue CC, McKoy JM, Evens AM, Trifilio SM, Tallman MS, Bennett CL. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant. 2007 Aug;40(3):185-92. doi: 10.1038/sj.bmt.1705722. Epub 2007 Jun 11.

    PubMed 17563736

  • Yanqing Z, Yu-Min L, Jian Q, Bao-Guo X, Chuan-Zhen L. Fibronectin and neuroprotective effect of granulocyte colony-stimulating factor in focal cerebral ischemia. Brain Res. 2006 Jul 7;1098(1):161-9. doi: 10.1016/j.brainres.2006.02.140. Epub 2006 Jul 11.

    PubMed 16814750

  • Schneider A, Kruger C, Steigleder T, Weber D, Pitzer C, Laage R, Aronowski J, Maurer MH, Gassler N, Mier W, Hasselblatt M, Kollmar R, Schwab S, Sommer C, Bach A, Kuhn HG, Schabitz WR. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest. 2005 Aug;115(8):2083-98. doi: 10.1172/JCI23559. Epub 2005 Jul 7.

    PubMed 16007267

  • Tsai KJ, Tsai YC, Shen CK. G-CSF rescues the memory impairment of animal models of Alzheimer's disease. J Exp Med. 2007 Jun 11;204(6):1273-80. doi: 10.1084/jem.20062481. Epub 2007 May 21.

    PubMed 17517969

  • Sanchez-Ramos J, Song S, Sava V, Catlow B, Lin X, Mori T, Cao C, Arendash GW. Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer's mice. Neuroscience. 2009 Sep 29;163(1):55-72. doi: 10.1016/j.neuroscience.2009.05.071. Epub 2009 Jun 14.

    PubMed 19500657

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Filgrastim (75mcg/0.3ml) in people with Alzheimer's Disease, run by Chang Gung Memorial Hospital at 1 site in Taiwan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Sep 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Alzheimer's Disease Assessment Scale, Cognitive subscale - Chinese version (ADAS-Cog-C) (time frame: 24 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03656042, which also lists 9 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2018.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in